Having problems viewing this e-mail ? November 2012 Registration opens for the PGIP quarterly meeting in Lansing Online registration is now open for the PGIP December 2012 Quarterly
Meeting at Lansing Community College-West campus. On-site
attendance is limited to medical and executive leadership at the morning
meeting with live streaming offered to an unlimited number of additional
participants. Specific interest group breakout sessions will also be
accessible via live streaming while others will provide remote access via
the AT&T conference call or webinar numbers.
BCBSM’s Value-Based Contracting Strategy will be discussed at December PGIP Quarterly Meeting Join us from 11:15 a.m. to 12:15 p.m., Dec. 7, 2012, at the PGIP
Quarterly Meeting in Lansing, Michigan, for an informational, open
discussion breakout session on BCBSM’s value-based hospital
contracting strategy. The session will take place in the Main Room
immediately following the morning meeting.
get the full benefit of PGIP Matters. PGIP grows with four new POs in 2013 PGIP will invite four new physician organizations to join PGIP for the
2013 program year. As contracted entities, the four POs are invited to
participate in activities such as the PGIP initiatives.
PGIP PA and Self-Assessment Data Tools to Replace the SRD in 2013 As presented at the September PGIP Quarterly meeting, Value
Partnerships has developed a new Web-based toolset to replace the
SRD beginning summer 2013. The PGIP Practitioner Alignment tool will
be used to maintain your PO physician list, and the Self-Assessment
Data tool will be used to report Practice Unit PCMH/Technical
August 2012 Progress Report – Summary Report and Informational Webinar Twice a year, PGIP conducts surveys of all the physician organizations
http://view.exacttarget.com/.7d137776&l=fe9816707367007c72&s=fe2610757c64037f701174&jb=ffcf14&ju=fe2c15757d640774721472[11/28/2012 12:32:05 PM]
to obtain important information on administrative function, capabilities
and performance on initiatives. The summary findings from the August
2012 survey titled, August 2012 Progress Report will be available on
Nov.19, 2012. The survey is an evaluation of PO initiative engagement
during a seven-month period, from February 2012 to August 2012).
These findings are also a key component in initiative evaluation by our
PGIP Grants Update In the November 2010 PGIP Matters, we reported on several newly
awarded grants aimed at evaluating various aspects of the BCBSM
Value Partnerships programs. At the time, researchers from the
University of Michigan and Michigan State University were awarded
more than $3.5 million to study and evaluate the programs and
determine their relevance on a national scale.
PGIP Journey available on the PO Collaborative site Seven years since the inception of the program, PGIP continues to lead
the way in health care transformation through the development of
innovative programs and initiatives that are improving the quality and
affordability of care throughout the state. To chronicle the PGIP journey
and to provide a glimpse of the “past, present, and future” of the
program, Value Partnerships created a document titled, The PGIPJourney: A Path to Healthcare Transformation.Generics for Singulair® and Singulair Chewable® now available. An important generic opportunity in Asthma and Allergy
Aug. 9 marked the official launch of Montelukast Sodium Tablets (10mg)
and Montelukast Sodium Chewable Tablets in 4mg and 5mg.
Montelukast, the FDA-approved generic for the brand name product
Singulair® represents an important addition to the growing list of major
generic drug products launched in 2012. Singulair® as a branded
product was responsible for national sales of $4 billion dollars per year.
In 2011, it represented the sixth highest drug expenditure for Blue Cross
Blue Shield of Michigan. Multiple manufacturers were available at the
time of launch, driving the price to nominal levels.
You have received this e-mail because you have registered with Blue Cross Blue Shield of Michigan. To ensure that you
continue to receive these e-mails, please add SubscriberEmail@bcbsm.com to your e-mail address book or safe-sender list.
This e-mail was sent to: suzan.hicks@stjohn.org
This e-mail was sent by: Blue Cross Blue Shield of Michigan
600 E. Lafayette, Detroit, MI, 48226, USA
For questions on PGIP Matters articles, contact Elizabeth Chouinard at.
http://view.exacttarget.com/.7d137776&l=fe9816707367007c72&s=fe2610757c64037f701174&jb=ffcf14&ju=fe2c15757d640774721472[11/28/2012 12:32:05 PM]
http://view.exacttarget.com/.7d137776&l=fe9816707367007c72&s=fe2610757c64037f701174&jb=ffcf14&ju=fe2c15757d640774721472[11/28/2012 12:32:05 PM]
COMMISSION DE LA TRANSPARENCE ARZERRA 100 mg, solution à diluer pour perfusion B/3 (CIP 577 117-9) B/10 (CIP 577 118-5) GLAXOSMITHKLINE Ofatumumab Code ATC: L01XC10 Liste I Médicament orphelin (7/11/2008) Médicament réservé à l’usage hospitalier. Prescription réservée aux spécialistes en oncologie ou hématologie ou aux médecins compétents en cancérologie. Médic
O termo «indução» tem origem na Filosofia. A entrada do Dicionário de Fi- losofia de Simon Blackburn que lhe diz respeito começa do seguinte modo: Indução Termo usado sobretudo para designar qualquer processo de raciocí- nio que nos conduza de premissas empíricas a conclusões empíricas, que,apesar de apoiadas pelas premissas, não são dedutivamente deriváveisdelas. Assim, in
Having problems viewing this e-mail ?